Berzosertib - Trial Rational Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA repair, “ATR kinase”. Blocking this…
Background Enhertu is a conjugate of an antibody which is anti-HER2 and chemo drug. Enhertu may have efficacy in patients with HER2-positive advanced gastric cancer. In a phase II trial,…
Background Pyrotinib is an innovative cancer drug targeting EGFR, HER2, and HER4 which are components expressed on cell surface. Pyrotinib plus Xeloda has shown meaningful benefits and acceptable side effects…
Colon cancer treated with Enhertu Enhertu is an antibody-drug conjugate composed of a chemotherapy bound to an anti-HER2 antibody. Recently, in December 2019, Enhertu received accelerated approval by the FDA…
About the two study drugs in Triple Negative Breast Cancer Both study drugs are FDA approved. Halaven is approved for advanced breast cancer and Keytruda for different cancer indications. As…
Background about Glioblastoma Glioblastoma, GBM, is an aggressive and the most frequent malignant brain tumor primary brain tumor with poor prognosis. At diagnosis, the standard treatment is largely confined to…
The FDA has approved Retevmo capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This is the first therapy approved to target RET gene…
Background Patients with advanced or metastatic kidney cancer are a population that despite recent advances remains in need of additional therapeutic options that extend survival. The immunotherapy and tyrosine kinase…
"Compassionate drugs", also called “named patient drugs” or “early access drugs”. Compassionate drugs can be one of three cases: Compassionate drugs (1) - Can be an experimental, investigational drug that…
Chondrosarcoma and IDH1 - Background For locally advanced and/or metastatic Chondrosarcoma, no known effective therapy exists. The standard protocols are not effective. Mutations in the IDH1/2 enzymes occur in up…